<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>6418</id>
    <completedYear/>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>reportzib</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2017-05-29</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies</title>
    <abstract language="eng">Background&#13;
We assessed the novel MACC1 gene to further stratify stage II colon cancer&#13;
patients with proficient mismatch repair (pMMR).&#13;
Patients and methods&#13;
Four cohorts with 596 patients were analyzed: Charité 1 discovery cohort&#13;
was assayed for MACC1 mRNA expression and MMR in cryo-preserved&#13;
tumors. Charité 2 comparison cohort was used to translate MACC1 qRT-&#13;
PCR analyses to FFPE samples. In the BIOGRID 1 training cohort MACC1&#13;
mRNA levels were related to MACC1 protein levels from&#13;
immunohistochemistry in FFPE sections; also analyzed for MMR.&#13;
Chemotherapy-naïve pMMR patients were stratified by MACC1 mRNA and&#13;
protein expression to establish risk groups based on recurrence-free&#13;
survival (RFS). Risk stratification from BIOGRID 1 was confirmed in the&#13;
BIOGRID 2 validation cohort. Pooled BIOGRID datasets produced a best&#13;
effect-size estimate.&#13;
Results&#13;
In BIOGRID 1, using qRT-PCR and immunohistochemistry for MACC1&#13;
detection, pMMR/MACC1-low patients had a lower recurrence probability&#13;
versus pMMR/MACC1-high patients (5-year RFS of 92% and 67% versus&#13;
100% and 68%, respectively). In BIOGRID 2, longer RFS was confirmed&#13;
for pMMR/MACC1-low versus pMMR/MACC1-high patients (5-year RFS of&#13;
100% versus 90%, respectively). In the pooled dataset, 6.5% of patients&#13;
were pMMR/MACC1-low with no disease recurrence, resulting in a 17%&#13;
higher 5-year RFS (95% CI (12.6-21.3%)) versus pMMR/MACC1-high&#13;
patients (P=0.037). Outcomes were similar for pMMR/MACC1-low and&#13;
deficient MMR (dMMR) patients (5-year RFS of 100% and 96%,&#13;
respectively).&#13;
Conclusions&#13;
MACC1 expression stratifies colon cancer patients with unfavorable pMMR&#13;
status. Stage II colon cancer patients with pMMR/MACC1-low tumors have&#13;
a similar favorable prognosis to those with dMMR with potential&#13;
implications for the role of adjuvant therapy.</abstract>
    <identifier type="issn">1438-0064</identifier>
    <identifier type="doi">10.1093/annonc/mdx207</identifier>
    <identifier type="urn">urn:nbn:de:0297-zib-64184</identifier>
    <enrichment key="SourceTitle">Appeared in: Annals of Oncology</enrichment>
    <author>Ulrich-Peter Rohr</author>
    <submitter>Marc Osterland</submitter>
    <author>Pia Herrmann</author>
    <author>Katharina Ilm</author>
    <author>Hai Zhang</author>
    <author>Sabine Lohmann</author>
    <author>Astrid Reiser</author>
    <author>Andrea Muranyi</author>
    <author>Janice Smith</author>
    <author>Susen Burock</author>
    <author>Marc Osterland</author>
    <author>Katherine Leith</author>
    <author>Shalini Singh</author>
    <author>Patrick Brunhoeber</author>
    <author>Rebecca Bowermaster</author>
    <author>Jeanne Tie</author>
    <author>Michael Christie</author>
    <author>Hui-Li Wong</author>
    <author>Paul Waring</author>
    <author>Kandavel Shanmugam</author>
    <author>Peter Gibbs</author>
    <author>Ulrike Stein</author>
    <series>
      <title>ZIB-Report</title>
      <number>17-28</number>
    </series>
    <collection role="msc" number="92-XX">BIOLOGY AND OTHER NATURAL SCIENCES</collection>
    <collection role="institutes" number="vis">Visual Data Analysis</collection>
    <collection role="projects" number="no-project">no-project</collection>
    <collection role="institutes" number="VDcC">Visual and Data-centric Computing</collection>
  </doc>
  <doc>
    <id>6389</id>
    <completedYear/>
    <publishedYear>2017</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>1869</pageFirst>
    <pageLast>1875</pageLast>
    <pageNumber/>
    <edition/>
    <issue>8</issue>
    <volume>28</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2017-04-28</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies</title>
    <abstract language="eng">Background&#13;
We assessed the novel MACC1 gene to further stratify stage II colon cancer patients with proficient mismatch repair (pMMR).&#13;
Patients and methods&#13;
Four cohorts with 596 patients were analyzed: Charité 1 discovery cohort was assayed for MACC1 mRNA expression and MMR in cryo-preserved tumors. Charité 2 comparison cohort was used to translate MACC1 qRT-PCR analyses to FFPE samples. In the BIOGRID 1 training cohort MACC1 mRNA levels were related to MACC1 protein levels from immunohistochemistry in FFPE sections; also analyzed for MMR. Chemotherapy-naïve pMMR patients were stratified by MACC1 mRNA and protein expression to establish risk groups based on recurrence-free survival (RFS). Risk stratification from BIOGRID 1 was confirmed in the BIOGRID 2 validation cohort. Pooled BIOGRID datasets produced a best effect-size estimate.&#13;
Results&#13;
In BIOGRID 1, using qRT-PCR and immunohistochemistry for MACC1 detection, pMMR/MACC1-low patients had a lower recurrence probability versus pMMR/MACC1-high patients (5-year RFS of 92% and 67% versus 100% and 68%, respectively). In BIOGRID 2, longer RFS was confirmed for pMMR/MACC1-low versus pMMR/MACC1-high patients (5-year RFS of 100% versus 90%, respectively). In the pooled dataset, 6.5% of patients were pMMR/MACC1-low with no disease recurrence, resulting in a 17% higher 5-year RFS (95% CI (12.6-21.3%)) versus pMMR/MACC1-high patients (P=0.037). Outcomes were similar for pMMR/MACC1-low and deficient MMR (dMMR) patients (5-year RFS of 100% and 96%, respectively).&#13;
Conclusions&#13;
MACC1 expression stratifies colon cancer patients with unfavorable pMMR status. Stage II colon cancer patients with pMMR/MACC1-low tumors have a similar favorable prognosis to those with dMMR with potential implications for the role of adjuvant therapy.</abstract>
    <parentTitle language="eng">Annals of Oncology</parentTitle>
    <identifier type="doi">10.1093/annonc/mdx207</identifier>
    <enrichment key="PeerReviewed">yes</enrichment>
    <enrichment key="PreprintUrn">urn:nbn:de:0297-zib-64184</enrichment>
    <author>Ulrich-Peter Rohr</author>
    <submitter>Marc Osterland</submitter>
    <author>Pia Herrmann</author>
    <author>Katharina Ilm</author>
    <author>Hai Zhang</author>
    <author>Sabine Lohmann</author>
    <author>Astrid Reiser</author>
    <author>Andrea Muranyi</author>
    <author>Janice Smith</author>
    <author>Susen Burock</author>
    <author>Marc Osterland</author>
    <author>Katherine Leith</author>
    <author>Shalini Singh</author>
    <author>Patrick Brunhoeber</author>
    <author>Rebecca Bowermaster</author>
    <author>Jeanne Tie</author>
    <author>Michael Christie</author>
    <author>Hui-Li Wong</author>
    <author>Paul Waring</author>
    <author>Kandavel Shanmugam</author>
    <author>Peter Gibbs</author>
    <author>Ulrike Stein</author>
    <collection role="institutes" number="vis">Visual Data Analysis</collection>
    <collection role="projects" number="no-project">no-project</collection>
    <collection role="institutes" number="VDcC">Visual and Data-centric Computing</collection>
  </doc>
</export-example>
